References
- Lee CH, Olson P, Evans RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201–2207
- Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor damma agonists: Their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 2006; 35: 561–574
- Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: Implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4: 257–291
- Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284–287
- Eftychi C, Howson JMM, Barratt BJ, Vella A, Payne F, Smyth DJ, Twells RCJ, Walker NM, Rance HE, Tuomilehto-Wolf E, Tuomilehto J, Undlien DE, Ronningen KS, Guja C, Ionescu-Tırgovishte C, Savage DA, Todd JA. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes 2004; 53: 870–873
- Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O. The Danish Society of Childhood Diabetes. IRS1, KCNJ11, PPARγ2 and HNF-1α: Do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?. Diabetes Obes Metab 2006; 8: 75–82
- Waden J, Thorn LM, Forsblom C, Lakka T, Saraheimo M, Rosengard-Barlund M, Heikkila O, Wessman M, Turunen JA, Parkkonen M, Tikkanen H, Groop P-H. Leisure-time physical activity is associated with the metabolic syndrome in type 1 diabetes. Effect of the PPARγ Pro12Ala polymorphism: The FinnDiane Study. Diabetes Care 2007; 30: 1618–1620
- Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: Principles of mapping polygenes. Annu Rev Genet 1996; 30: 343–370
- Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: Implications for human type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 114–117
- Botolin S, Faugere M-C, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice. Endocrinology 2005; 146: 3622–3631
- Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178–182
- Jacob S. The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000; 32: 413–416
- Ek J. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 2001; 44: 1170–1176
- Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 1998; 391: 79–82
- Augstein P, Dunger A, Heinke P, Wachlin G, Berg S, Hehmke B, Salzsieder E. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378–384